An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy
Hepatotoxicity is a well-documented complication of induction chemotherapy for acute lymphoblastic leukemia (ALL), but our understanding of its biological mechanisms is limited. We identified 314 patients with ALL (aged 1-19 years) treated at Texas Children's Hospital (2008-2019) with diagnostic bone marrow plasma available for metabolomic profiling: 234 for discovery and 80 for replication. Hepatotoxicity during induction was defined as follows: (1) transaminitis: grade ≥3 aspartate aminotransferase or alanine aminotransferase or (2) conjugated hyperbilirubinemia: conjugated bilirubin (c.bili) >3 mg/dL. Untargeted profiling detected 519 metabolites. Adjusted odds ratios (aORs) for each metabolite were calculated with logistic regression, accounting for sex, age, body mass index, race/ethnicity, and treatment intensity. The population was 56% Latino, 57% male, 92% B-ALL, 25% overweight/obese, and 57% National Cancer Institute standard-risk at a median age of 5 years. Transaminitis was observed in 34% of the discovery and 24% of the replication cohort. Seven instances of c.bili >3 mg/dL were observed in the discovery cohort, with none in the replication cohort. Furthermore, 12 metabolites were associated with transaminitis (P < .05) in the discovery cohort, including 2 that replicated (P < .05): 1,2-dipalmitoyl-glycerophosphocholine (GPC) (aOR combined = 1.88 [95% confidence interval [CI], 1.26-2.79], P = .002) and 1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (aOR combined = 1.56 [95% CI: 1.17-2.09], P = .003). In the discovery cohort, 34 metabolites were associated with c.bili >3 mg/dL, including the top association of 1,2-dipalmitoyl-GPC (aOR = 5.76 [95% CI: 2.20-23.16], P = .002). We observed and replicated associations between phosphatidylcholine metabolites at ALL diagnosis and hepatotoxicity during induction therapy, suggesting a potential role for lipid dysregulation in the development of hepatotoxicity.
Authors
- Kathleen Ludwig
- Michael E. Scheurer (ORCID: https://orcid.org/0000-0002-8379-6088)
- Juan Carlos Bernini
- Karen R. Rabin (ORCID: https://orcid.org/0000-0002-4081-8195)
- Laura J. Klesse (ORCID: https://orcid.org/0000-0003-1323-7720)
- Steven D. Mittelman (ORCID: https://orcid.org/0000-0003-2867-1298)
- M. Brooke Bernhardt (ORCID: https://orcid.org/0000-0002-9612-3624)
- Van Huynh (ORCID: https://orcid.org/0000-0002-2781-5627)
- Etan Orgel (ORCID: https://orcid.org/0000-0002-1487-6818)
- Sandi L. Pruitt (ORCID: https://orcid.org/0000-0002-1007-9176)
- Austin L. Brown (ORCID: https://orcid.org/0000-0001-5802-5073)
- Maria Monica Gramatges (ORCID: https://orcid.org/0000-0002-0947-104X)
- Hong Zhu (ORCID: https://orcid.org/0000-0001-8562-3351)
- John P. Woodhouse
- Rodrigo Eraña
- M. Roberts
- Philip J. Lupo (ORCID: https://orcid.org/0000-0003-0978-5863)
- A. Lauren Crain (ORCID: https://orcid.org/0000-0002-5050-945X)
- Kenneth Heym (ORCID: https://orcid.org/0000-0002-6635-435X)
- Olga A. Taylor
- Jeremy M. Schraw (ORCID: https://orcid.org/0000-0002-6674-9562)
- Ashley Chavana
- Timothy Griffin
- Emily J. Mason (ORCID: https://orcid.org/0000-0001-8120-2138)
Institutions
- Children's Hospital of Orange County (US)
- St. Jude Children's Research Hospital (US)
- Children's Hospital of Los Angeles (US)
- Emory University (US)
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- UCLA Health (US)
- Texas Oncology (US)
- Cook Children's Medical Center (US)
- Children's Hospital of San Antonio (US)
- Southwestern Medical Center (US)
- Texas Children's Hospital (US)
- Children's Cancer Center (US)
- Southwestern Medical Center (US)
- University of Virginia (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1182/bloodadvances.2025016978
- Citations
- 2
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 3.11